Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEVA-OV3
- Development stage
- Preclinical
- Lead developer
- Devacell
- Modality
- Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
**DEVA-OV3** is a preclinical Devacell ONCoat-based synthetic, replication-competent adenovirus subtype 5 oncolytic immunotherapy for solid tumors. The engineered vector is intended to directly lyse tumor cells and promote immunogenic cell death while locally expressing a combination of checkpoint-directed and cytokine immunomodulatory transgenes associated with PD-1, PD-L1, CTLA-4, IL-12, and IL-15 to enhance antitumor innate and adaptive immune responses. ([devacell.com](https://devacell.com/pipeline/))
- Other names
- DEVAOV3DEVAOV-3DEVAOV 3
02
Targets
IL15 (Interleukin 15)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IL12 (Interleukin-12)
Beyond the preview
Go deeper on DEVA-OV3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEVA-OV3.